Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin"
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study was to assess safety of antithrombotic drug ticagrelor plus oral
anticoagulation adopted in persistent or permanent AF(Atrial fibrillation)
patients（CHA2DS2VASc≥2） after PCI-S with specially regard to the occurrence of major bleeding
complications. We hypothesized that baseline characteristics (ie age, anemia, previous major
bleeding) and type of antithrombotic regimen could influence any bleeding events and the time
of bleeding occurrence. We will test this hypothesis by comparing those AF patients who
subsequently received double antithrombotic therapy (Ticagrelor + Warfarin) vs. triple
antithrombotic therapy (Clopidogrel + Aspirin + Warfarin) after undergoing PCI-S.